Cost of Care for the Initial Management of Ovarian Cancer
Authors:
- 1 December 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 130 (6) , 1269-1275
Abstract
OBJECTIVE: To examine the cost of care during the first year after a diagnosis of ovarian cancer, estimate the sources of cost, and explore the out-of-pocket costs. METHODS: We performed a retrospective cohort study of women with ovarian cancer diagnosed from 2009 to 2012 who underwent both surgery and adjuvant chemotherapy using the Truven Health MarketScan database. This database is comprised of patients covered by commercial insurance sponsored by more than 100 employers in the United States. Medical expenditures, including physician reimbursement, for a 12-month period beginning on the date of surgery were estimated. All payments were examined, including out-of-pocket costs for patients. Payments were divided into expenditures for inpatient care, outpatient care (including chemotherapy), and outpatient drug costs. The 12-month treatment period was divided into three phases: surgery to 30 days (operative period), 1–6 months (adjuvant therapy), and 6–12 months after surgery. The primary outcome was the overall cost of care within the first year of diagnosis of ovarian cancer; secondary outcomes included assessment of factors associated with cost. RESULTS: A total of 26,548 women with ovarian cancer who underwent surgery were identified. After exclusion of patients with incomplete insurance enrollment or coverage, those who did not undergo chemotherapy, and those with capitated plans, our cohort consisted of 5,031 women. The median total medical expenditures per patient during the first year after the index procedure were $93,632 (interquartile range $62,319–140,140). Inpatient services accounted for $30,708 (interquartile range $20,102–51,107; 37.8%) in expenditures, outpatient services $52,700 (interquartile range $31,210–83,206; 58.3%), and outpatient drug costs $1,814 (interquartile range $603–4,402; 3.8%). The median out-of-pocket expense was $2,988 (interquartile range $1,649–5,088). This included $1,509 (interquartile range $705–2,878) for outpatient services, $589 (interquartile range $3–1,715) for inpatient services, and $351 (interquartile range $149–656) for outpatient drug costs. CONCLUSION: The average cost of care for women with ovarian cancer in the first year after surgery is approximately $100,000. Patients bear approximately 3% of these costs in the form of out-of-pocket expenses.Keywords
This publication has 20 references indexed in Scilit:
- Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With CancerJAMA Oncology, 2017
- Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian CancerObstetrics & Gynecology, 2016
- The Cost of Initial Care for Medicare Patients With Advanced Ovarian CancerJournal of the National Comprehensive Cancer Network, 2016
- Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot studyThe Lancet Haematology, 2015
- Costs of treatment for elderly women with advanced ovarian cancer in a Medicare populationGynecologic Oncology, 2015
- Association Between Hospital Conversions to For-Profit Status and Clinical and Economic OutcomesJAMA, 2014
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III TrialJournal of Clinical Oncology, 2014
- Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancerCancer, 2014
- Limits on Medicare's Ability to Control Rising Spending on Cancer DrugsNew England Journal of Medicine, 2009
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987